Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tirat Carmel Mental Health Center
With
University of Michigan
Ariel University
The Nazareth Hospital, Israel
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
1. Men and women 18-65 age old
2. Patients with DSM-IV (or/and ICD-10) diagnosis MDD
3. Volunteers without DSM-IV (or/and ICD-10) diagnosis MDD
4. For patients with DSM-IV (or/and ICD-10) diagnosis MDD minimum 2 weeks free from benzodiazepines, mood stabilizers and neuroleptics.
5. All patients from MDD group treatment only by SSRI antidepressant medications.
You may not be if
1. MDD with Co-morbidity
2. Alcohol and drug use less than 1 month before the study
Clareo Health | Assessment of Pituitary Adenylate Cyclase Activating Polypeptide-Brain Derived Neurotrophic Factor (PACAP-BDNF) Signaling System Involvement in Etiology and Treatment of Major Depression
